Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

US stocks closed in the red Tuesday as investors digested a wave of corporate earnings and economic data, while bracing for ...

-U.S. futures for the S&P 500 and Dow Jones Industrial Average rose 0.1% and Nasdaq futures gained 0.3%. Earnings will come today from Boeing, Spotify, United Health, Procter & Gamble, Visa and PayPal ...

US stocks gave up earlier gains on Tuesday as investors digested a wave of corporate earnings and economic data, while ...

US stocks pared earlier small gains on Tuesday, but kept a bid for more records in play as investors combed through a rush of corporate earnings and economic data key to the odds of interest-rate cuts ...

Wall Street traders left stocks at all-time highs while the dollar climbed the most since May, with a tariff deal between ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Despite all the buzz around Sarepta and concerns about Elevidys, industry watchers aren’t convinced this current controversy ...

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...